ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,437.40
      1.15%
      US Tech 100
      18,973.60
      1.35%
      Dow Jones
      38,810.69
      0.16%
      Brent Oil
      82.275
      0.34%
      Bitcoin
      68,830.50
      2.24%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. TransCode Therapeutics Inc (RNAZ)

      7. TransCode Therapeutics Inc (RNAZ) News

      RNAZ

      TransCode Therapeutics (RNAZ)

      TransCode Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RNAZ
      DateTimeSourceHeadlineSymbolCompany
      06/10/20248:45AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
      06/10/20247:00AMGlobeNewswire Inc.Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
      06/07/20244:00PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
      06/07/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
      05/29/20249:15AMGlobeNewswire Inc.TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
      05/20/20244:00PMEdgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RNAZTransCode Therapeutics Inc
      05/15/20245:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
      05/13/20245:08PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
      05/13/20248:30AMGlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
      05/10/20244:50PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
      05/10/20244:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
      04/15/20249:00AMGlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
      04/03/20249:10AMGlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
      03/28/20248:30AMGlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
      03/11/20249:00AMGlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
      03/06/20244:15PMGlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
      02/20/20248:00AMGlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
      02/15/20244:00PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
      02/13/20248:12PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
      01/31/20244:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
      01/31/20244:05PMGlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketNASDAQ:RNAZTransCode Therapeutics Inc
      01/29/20248:30AMGlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerNASDAQ:RNAZTransCode Therapeutics Inc
      01/22/20244:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
      01/22/20244:45PMGlobeNewswire Inc.TransCode Therapeutics Announces Closing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
      01/19/20249:57PMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RNAZTransCode Therapeutics Inc
      01/19/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
      01/18/20241:27PMGlobeNewswire Inc.TransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
      01/18/202410:39AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
      01/17/20247:06AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
      01/16/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:RNAZ